Pancreatic Cancer: Advances in Treatment and Future Prospects

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by an aggressive biological profile, late-stage diagnosis, and limited response to existing therapies. Despite significant advancements in our understanding of the molecular and cellular biology of PDAC, its prognosis continues to be poor, with a five-year survival rate of less than 10%. These outcomes are largely driven by the tumor’s complex biology, its propensity for early dissemination, and the challenges in achieving timely diagnosis.

Recent research has provided critical insights into the genetic and molecular landscape of PDAC, offering new opportunities for early detection and targeted therapies. Biomarkers for early diagnosis and risk stratification are an area of active exploration, with the potential to identify patients at earlier, more treatable stages of the disease. Surgical resection remains the cornerstone of curative treatment, yet it is only feasible in a minority of cases due to late-stage presentation. Advances in surgical techniques, including minimally invasive and robotic approaches, aim to optimize patient outcomes while minimizing perioperative morbidity. Moreover, managing postoperative complications, such as pancreatic fistulas, remains a key challenge in improving recovery and long-term survival.

Neoadjuvant and adjuvant therapies are increasingly being integrated into the standard of care, offering opportunities to downstage borderline resectable tumors and enhance the effectiveness of surgery. However, the optimal sequencing, combination, and personalization of these therapies are subjects of ongoing research and debate.

This Special Issue of Medicina focuses on the intersection of tumor biology, early detection, surgical innovation, and multimodal therapy in pancreatic cancer. We aim to highlight cutting-edge research and clinical advances in the following areas:

• Tumor biology and the genetic and molecular mechanisms driving PDAC progression;
• Biomarkers and novel strategies for early diagnosis and risk stratification;
• Innovations in surgical techniques, including robotic and minimally invasive approaches;
• Management and prevention of postoperative complications;
• Advances in neoadjuvant and adjuvant therapy protocols and their integration into clinical practice.

By gathering contributions from leading experts, this Special Issue seeks to provide a deeper understanding of the disease and its management, with the ultimate goal of improving early detection and optimizing therapeutic strategies to enhance patient outcomes.

Dr. Damiano Caputo
Guest Editor

Dr. Roberto Cammarata
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pancreatic cancer
• pancreatic ductal adenocarcinoma (PDAC)
• biomarkers
• neoadjuvant therapy
• adjuvant therapy
• robotic surgery
• minimally invasive surgery
• precision medicine
• multidisciplinary care
• post-operative complications